BioSpace News Archive

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations at the Cantor Fitzgerald Virtual Global Healthcare Conference and the Morgan Sta

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled to present at two upcoming healthcare investor conferences: Baird 2020 Global Healthcare Conference Date: Thursday, September 10, 2020 Presentation Time: 11:25 a.m. ET Morgan Stanley 18th Annual Global He

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced a joint proof-of-concept program. StemoniX and vivo Pharm ® , a subsidiary of Cancer Genetics, recently launched a joint proof-of-concept p

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced sales for the month of August 2020 were $1,190,000. This compares with sales for the month of July 2020 of $550,000, with growth driven by week

AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020.

- Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine) tablets, Rebif® (interferon beta-1a) and investigational evobrutinib - New data and real-world evidence further characterize the efficacy and safety profiles of MAVENCLAD® - New MAVENCLAD® and Rebif® safety data to be shared regarding risk of respiratory viral infections

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials.

Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. Ed Rebar , Ph.D., joins the company as Chief Technology Officer and Terry Fry , M.D. joins as SVP, Head of T Cell Therapeutics.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of P

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s